Advertisement

Journal of Molecular Modeling

, Volume 18, Issue 4, pp 1583–1589 | Cite as

Trimethylaurintricarboxylic acid inhibits human DNA methyltransferase 1: insights from enzymatic and molecular modeling studies

  • Jakyung Yoo
  • José L. Medina-FrancoEmail author
Original Paper

Abstract

DNA methyltransferase 1 (DNMT1) is an emerging target for the treatment of cancer, brain disorders, and other diseases. Currently, there are only a few DNMT1 inhibitors with potential application as therapeutic agents or research tools. 5,5-Methylenedisalicylic acid is a novel scaffold previously identified by virtual screening with detectable although weak inhibitory activity of DNMT1 in biochemical assays. Herein, we report enzyme inhibition of a structurally related compound, trimethylaurintricarboxylic acid (NSC97317) that showed a low micromolar inhibition of DNMT1 (IC50 = 4.79 μM). Docking studies of the new inhibitor with the catalytic domain of DNMT1 suggest that NSC97317 can bind into the catalytic site. Interactions with amino acid residues that participate in the mechanism of DNA methylation contribute to the binding recognition. In addition, NSC97317 had a good match with a structure-based pharmacophore model recently developed for inhibitors of DNMT1. Trimethylaurintricarboxylic acid can be a valuable biochemical tool to study DNMT1 inhibition in cancer and other diseases related to DNA methylation.

Figure

Trimethylaurintricarboxylic acid (NSC97317) is a novel and low micromolar inhibitor of DNMT1

Keywords

Cancer DNMT Docking Enzyme inhibition Epigenetics Methyltransferase 

Notes

Acknowledgments

NSC97317 was kindly supplied by the Drug Synthesis and Chemistry Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute. This work was supported by the Menopause & Women’s Health Research Center and the State of Florida, Executive Office of the Governor’s Office of Tourism, Trade, and Economic Development. Authors are grateful to Kyle Kryak for proofreading the manuscript.

References

  1. 1.
    Robertson KD (2001) DNA methylation, methyltransferases, and cancer. Oncogene 20:3139–3155CrossRefGoogle Scholar
  2. 2.
    Yokochi T, Robertson KD (2002) Preferential methylation of unmethylated DNA by mammalian de novo DNA methyltransferase Dnmt3a. J Biol Chem 277:11735–11745CrossRefGoogle Scholar
  3. 3.
    Goll MG, Bestor TH (2005) Eukaryotic cytosine methyltransferases. Annu Rev Biochem 74:481–514CrossRefGoogle Scholar
  4. 4.
    Sippl W, Jung M (2009) DNA Methyltransferase inhibitors, vol. 42 Epigenetic Targets in Drug Discovery. Wiley-VCH, WeinheimCrossRefGoogle Scholar
  5. 5.
    Stresemann C, Lyko F (2008) Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer 123:8–13CrossRefGoogle Scholar
  6. 6.
    Kelly TK, De Carvalho DD, Jones PA (2010) Epigenetic modifications as therapeutic targets. Nat Biotechnol 28:1069–1078CrossRefGoogle Scholar
  7. 7.
    Portela A, Esteller M (2010) Epigenetic modifications and human disease. Nat Biotechnol 28:1057–1068CrossRefGoogle Scholar
  8. 8.
    Zawia NH, Lahiri DK, Cardozo-Pelaez F (2009) Epigenetics, oxidative stress, and Alzheimer disease. Free Radical Biol Med 46:1241–1249CrossRefGoogle Scholar
  9. 9.
    Miller CA, Gavin CF, White JA, Parrish RR, Honasoge A, Yancey CR, Rivera IM, Rubio MD, Rumbaugh G, Sweatt JD (2010) Cortical DNA methylation maintains remote memory. Nat Neurosci 13:664–666CrossRefGoogle Scholar
  10. 10.
    Narayan P, Dragunow M (2010) Pharmacology of epigenetics in brain disorders. Br J Pharmacol 159:285–303CrossRefGoogle Scholar
  11. 11.
    Cheng XD, Blumenthal RM (2008) Mammalian DNA methyltransferases: A structural perspective. Structure 16:341–350CrossRefGoogle Scholar
  12. 12.
    Lan J, Hua S, He XN, Zhang Y (2010) DNA methyltransferases and methyl-binding proteins of mammals. Acta Biochim Biophys Sin 42:243–252CrossRefGoogle Scholar
  13. 13.
    Jurkowska RZ, Jurkowski TP, Jeltsch A (2011) Structure and function of mammalian DNA methyltransferases. ChemBioChem 12:206–222CrossRefGoogle Scholar
  14. 14.
    Vilkaitis G, Merkiene E, Serva S, Weinhold E, Klimasauskas S (2001) The mechanism of DNA cytosine-5 methylation - Kinetic and mutational dissection of HhaI methyltransferase. J Biol Chem 276:20924–20934CrossRefGoogle Scholar
  15. 15.
    Schermelleh L, Spada F, Easwaran HP, Zolghadr K, Margot JB, Cardoso MC, Leonhardt H (2005) Trapped in action: direct visualization of DNA methyltransferase activity in living cells. Nat Methods 2:751–756CrossRefGoogle Scholar
  16. 16.
    Issa JPJ, Kantarjian HM, Kirkpatrick P (2005) Azacitidine. Nat Rev Drug Discovery 4:275–276CrossRefGoogle Scholar
  17. 17.
    Schrump DS, Fischette MR, Nguyen DM, Zhao M, Li XM, Kunst TF, Hancox A, Hong JA, Chen GA, Pishchik V, Figg WD, Murgo AJ, Steinberg SM (2006) Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin Cancer Res 12:5777–5785CrossRefGoogle Scholar
  18. 18.
    Issa J-PJ, Kantarjian HM (2009) Targeting DNA methylation. Clinical Cancer Res 15:3938–3946CrossRefGoogle Scholar
  19. 19.
    Lyko F, Brown R (2005) DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. J Natl Cancer Inst 97:1498–1506CrossRefGoogle Scholar
  20. 20.
    Yu N, Wang M (2008) Anticancer drug discovery targeting DNA hypermethylation. Curr Med Chem 15:1350–1375CrossRefGoogle Scholar
  21. 21.
    Hauser AT, Jung M (2008) Targeting epigenetic mechanisms: Potential of natural products in cancer chemoprevention. Planta Med 74:1593–1601CrossRefGoogle Scholar
  22. 22.
    Siedlecki P, Boy RG, Musch T, Brueckner B, Suhai S, Lyko F, Zielenkiewicz P (2006) Discovery of two novel, small-molecule inhibitors of DNA methylation. J Med Chem 49:678–683CrossRefGoogle Scholar
  23. 23.
    Kuck D, Caulfield T, Lyko F, Medina-Franco JL (2010) Nanaomycin A selectively inhibits DNMT3B and reactivates silenced tumor suppressor genes in human cancer cells. Mol Cancer Ther 9:3015–3023CrossRefGoogle Scholar
  24. 24.
    Medina-Franco JL, Caulfield T (2011) Advances in the computational development of DNA methyltransferase inhibitors. Drug Discovery Today 16:418–425CrossRefGoogle Scholar
  25. 25.
    Kuck D, Singh N, Lyko F, Medina-Franco JL (2010) Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem 18:822–829CrossRefGoogle Scholar
  26. 26.
    Podvinec M, Lim SP, Schmidt T, Scarsi M, Wen D, Sonntag L-S, Sanschagrin P, Shenkin PS, Schwede T (2010) Novel inhibitors of dengue virus methyltransferase: Discovery by in vitro-driven virtual screening on a desktop computer grid. J Med Chem 53:1483–1495CrossRefGoogle Scholar
  27. 27.
    Milani M, Mastrangelo E, Bollati M, Selisko B, Decroly E, Bouvet M, Canard B, Bolognesi M (2009) Flaviviral methyltransferase/RNA interaction: Structural basis for enzyme inhibition. Antiviral Res 83:28–34CrossRefGoogle Scholar
  28. 28.
    Bouvet M, Debarnot C, Imbert I, Selisko B, Snijder EJ, Canard B, Decroly E (2010) In vitro reconstitution of SARS-coronavirus mRNA cap methylation. Plos Pathogens 6:13CrossRefGoogle Scholar
  29. 29.
    Developmental Therapeutics Program. National Cancer Institute (NCI) http://dtp.cancer.gov
  30. 30.
    Reaction Biology Corporation. http://www.reactionbiology.com
  31. 31.
    Yoo J, Medina-Franco JL (2011) Homology modeling, docking and structure-based pharmacophore of inhibitors of DNA methyltransferase. J Comput Aided Mol Des 25:555–567Google Scholar
  32. 32.
    Yoo J, Medina-Franco JL (2011) Rundfeldt C (ed) Discovery and optimization of inhibitors of DNA methyltransferase as novel drugs for cancer therapy. Drug Development. InTech (in press)Google Scholar
  33. 33.
    The UniProt C The Universal Protein Resource (UniProt) (2010) Nucleic Acids Res 38(suppl 1):D142–D148Google Scholar
  34. 34.
    Song J, Rechkoblit O, Bestor TH, Patel DJ (2011) Structure of DNMT1-DNA complex reveals a role for autoinhibition in maintenance DNA methylation. Science 331:1036–1040CrossRefGoogle Scholar
  35. 35.
    Loving K, Salam NK, Sherman W (2009) Energetic analysis of fragment docking and application to structure-based pharmacophore hypothesis generation. J Comput Aided Mol Des 23:541–554CrossRefGoogle Scholar
  36. 36.
    Salam NK, Nuti R, Sherman W (2009) Novel method for generating structure-based pharmacophores using energetic analysis. J Chem Inf Model 49:2356–2368CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  1. 1.Torrey Pines Institute for Molecular StudiesPort St. LucieUSA

Personalised recommendations